PB-201

DRUG2 trials

Sponsors

PegBio Co., Ltd.

Conditions

Type 2 Diabetes MellitusType 2 Diabetes Mellitus (T2DM)

Phase 3

Study to Evaluate the Safety and Efficacy of PB-201 in Treatment-naive Patients With Type 2 Diabetes Mellitus

PegBio Co., Ltd.Type 2 Diabetes Mellitus (T2DM)

Start: 2021-09-30End: 2025-04-30Target: 672Updated: 2022-02-08

Study to Evaluate the Efficacy and Safety of PB-201 in Type 2 Diabetic Mellitus Patients With Poor Glycemic Control Via Metformin Hydrochloride Monotherapy

PegBio Co., Ltd.Type 2 Diabetes Mellitus

Start: 2022-05-30End: 2024-10-31Target: 546Updated: 2022-04-22

Related Papers

A multicentre, randomized, double‐blind, parallel, active‐ and placebo‐controlled Phase 3 clinical study of the glucokinase activator <scp>PB</scp> ‐201 in treatment‐naive patients with type 2 diabetes mellitus: A study protocol

Diabetes Obesity and Metabolism2022-10-307 citations

Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial.

2022-05-1253 citations